AI Drug Discovery for Pharma and Biotech

Drug discovery

111

drugs

With orphan designations

Overview

Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by abnormal, sickle-shaped red blood cells that cause vaso-occlusion, chronic hemolytic anemia, and multiorgan damage. Clinical manifestations include acute pain crises, stroke, infections, and progressive organ dysfunction. Management integrates disease-modifying therapies (e.g., hydroxyurea, gene therapies) and supportive care to reduce complications and improve quality of life [1][3][11].

Population

  • Affects ~100,000 Americans, predominantly non-Hispanic Black individuals (1 in 365 births) and Hispanic Americans (1 in 16,300 births) [2][17].

  • Global prevalence exceeds 7.7 million, with 80% of cases in sub-Saharan Africa [9][14]. Newborn incidence is rising, projected to reach 400,000 annual births by 2050 [14][15].

Burden

  • Reduces US life expectancy by >20 years; in low-resource settings, ≤90% mortality before adulthood [4][7][14].

  • Total mortality burden reached 376,000 deaths globally in 2021, 11× higher than cause-specific estimates [4][9].

  • Complications drive frequent hospitalizations, with high socioeconomic vulnerability in 67% of US cases [2][10].

Therapies

  • Disease-modifying: Hydroxyurea, L-glutamine, crizanlizumab, voxelotor

  • Curative: Stem cell transplantation, gene therapies (CASGEVY™, LYFGENIA™) [3][8][13]

  • Supportive care: Transfusions, pain management, penicillin prophylaxis [6][8]

Categories: rare genetic diseases, rare hematological diseases, rare transplant-related disorders

Research Papers

1,734 drug discovery papers about Sickle cell disease and related diseases, with 3 first-in-class and 57 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

1,734 drug discovery papers about Sickle cell disease and related diseases, with 3 first-in-class and 57 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

2026-09-06 | Kenya Sickle Cell Disease Public Health Literacy & Expert Insights Dataset (De-Identified FGDs, KIIs & Surveys)

This dataset contains de-identified qualitative and survey data collected to understand public health literacy, care experiences, and expert perspectives on sickle cell disease (SCD) in Kenya. The collection includes transcripts from Focus Group Discussions (FGDs) with people living with SCD and caregivers, Key Informant Interviews (KIIs) with Ministry of Health officials, healthcare providers, community representatives, and community health promoters (CHPs), as well as technical expert discussions and structured survey responses. The dataset captures themes related to SCD awareness, diagnosis and treatment pathways, access to care, psychosocial challenges, health information needs, health system barriers, and opportunities for improving community-based support and public health communication. All personal identifiers have been removed to protect participant confidentiality. This resource is intended to support research in public health, health communication, digital health, implementation science, and AI-enabled health systems, and provides contextual insights for the development of culturally appropriate interventions and evidence-based decision support tools for sickle cell disease in low-resource settings.

Open article ↗



2026-08-14 | Augmenting hemopexin-mediated heme scavenging mitigates sepsis-induced acute kidney injury in humanized sickle cell mice.

Sickle cell disease (SCD) is characterized by chronic intravascular hemolysis and depletion of the heme scavenger hemopexin (HPX), generating a high-heme milieu that may increase susceptibility to inflammatory organ injury. Sepsis is a leading cause of acute kidney injury (AKI), yet the contribution of hemolysis-derived free heme to polymicrobial sepsis-associated AKI in SCD remains poorly defined. Using humanized SCD mice, we tested whether augmenting heme clearance via HPX mitigates septic AKI. Low-grade cecal ligation and puncture induced exaggerated systemic inflammation, elevated circulating heme and ferritin, and marked reductions in glomerular filtration rate (GFR) in sickling (hemoglobin SS [HbSS]) mice compared with nonsickling (HbAA) control mice. Septic SS mice also exhibited enhanced renal nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome activation, increased oxidative stress, and tubular injury, consistent with heme-driven inflammatory and cytotoxic signaling. Acute administration of purified human HPX reduced circulating heme and ferritin, attenuated cytokine responses, and preserved GFR, indicating that restoration of heme buffering in SCD interrupts kidney injury pathways during septic stress. To achieve sustained heme control, we restored HPX expression using liver-directed delivery of adeno-associated virus serotype 8 (AAV8). AAV8-HPX restored hepatic HPX, reduced basal and sepsis-induced plasma heme levels, conferred protection against kidney dysfunction and tubular stress, and improved survival without evidence of hepatotoxicity. Collectively, these findings identify free heme as a central mediator linking hemolysis to sepsis-associated AKI in SCD, and establish that HPX augmentation via protein replacement or gene therapy is a mechanistically targeted, potentially translatable therapeutic strategy to mitigate heme-driven tissue injury and improve outcomes in SCD-associated sepsis.

Open article ↗



2026-08-06 | An ancient mitochondrial program tunes translation to haem availability.

Anaemia is a major global health burden that affects one-quarter of the human population and annually accounts for over 50 million years of healthy life lost1. It arises from nutritional iron deficiency, hereditary disorders (including thalassaemia and sickle cell disease) and malaria, and is characterized by haemoglobin imbalances2. Haem-the active component of haemoglobin-is both essential and potentially toxic, which necessitates tight control of levels. However, the molecular circuitry that monitors haem levels remains obscure. The cytosolic eIF2α kinase HRI counteracts anaemia amid iron deficiency or thalassaemia3,4 by acting as a gatekeeper of translation during erythroid differentiation, which has been attributed to its haem-binding ability5. Here we uncover that haem scarcity is sensed inside mitochondria through an OMA1-DELE1 axis. Mechanistically, haem deficiency triggers OMA1-dependent mitochondrial release of DELE1. In the cytosol, DELE1 releases inhibitory haem from HRI, which enables modifications in a crucial disordered segment of the kinase. We demonstrate that this sensor-actuator operates across human tissues, including erythroid progenitors, and is evolutionarily conserved down to bloodless invertebrates, thus predating the emergence of haemoglobin-based oxygen transport. Notably, pharmacological manipulation of this system enhances fetal globin expression-a central therapeutic objective in haemoglobinopathies. Together, these results reveal a primordial sentinel system that safeguards against haem-related toxicity from the single-cell to the organismic scale.

Open article ↗



2026-08-06 | Biomarker implications of gene editing in hematologic diseases: latest updates from ASH 2025.

The 2025 American Society of Hematology (ASH) Annual Meeting highlighted rapid advances in gene editing for hematologic diseases, with increasing emphasis on precision editing and early exploration of in vivo delivery strategies. Beyond technological development, several measurable parameters are emerging as potential biomarkers, including fetal hemoglobin (HbF), F-cell proportion, HbF/F-cell, editing durability, and long-term clonal monitoring. Clinical studies demonstrated that disruption of the BCL11A enhancer or editing of the HBG1/2 promoter can induce sustained HbF reactivation, which is associated with reduced transfusion burden or transfusion independence in transfusion-dependent β-thalassemia and improved clinical outcomes in sickle cell disease. Near-pancellular HbF distribution and HbF/F-cell levels above anti-sickling thresholds further support the pharmacodynamic value of HbF-related biomarkers. Long-term follow-up studies have also incorporated editing durability and clonal monitoring into safety assessment frameworks. Emerging platforms such as RNA Gene Writer and CD90-targeted virus-like particles have demonstrated the feasibility of in vivo hematopoietic stem cell editing, although challenges related to targeting efficiency, delivery specificity, immunogenicity, and long-term safety remain. Overall, ASH 2025 suggests a shift from achieving gene editing to quantifying efficacy, durability, and safety, with standardized biomarker frameworks likely to play an increasingly important role in future clinical translation.

Open article ↗



2026-07-28 | Public knowledge, attitudes, and ethical views on CRISPR-Cas9 gene editing for genetic diseases in Taif, Saudi Arabia.

Public support for gene editing, particularly for therapeutic purposes, remains strong. Recently, the Ministry of Health in Saudi Arabia approved CRISPR-Cas9 for treating Sickle Cell Disease and beta thalassemia. This study aims to assess the Taif population's opinion on gene editing and their knowledge of genetic modification. In this cross-sectional study, a questionnaire was distributed online from March 2, 2024, to June 15, 2024, to 747 residents of Taif City aged 18 and older. Among the respondents, 14.7% reported that they or their family members suffer from a hereditary disease, and 65.7% either work or study in the healthcare field or have a family member involved in healthcare. Additionally, 50.7% had previously heard of genetic modification. Marital status, number of children, and education level did not significantly influence opinions on genetic editing, whereas affiliation with the healthcare field was significantly associated with greater acceptance (p = 0.023), while a family history of hereditary disease showed a trend toward significance (p = 0.055). Public opinion strongly supports using genetic editing to treat life-threatening diseases in adults and embryos (63.2% and 73.6%, respectively). However, opinions are more divided on non-disease traits. Many respondents expressed interest in enhancing intelligence (73.8%) and strength (75.8%), as well as altering height (67.8%) and hair color (60.7%). While support was strong for therapeutic use, opinions were divided on enhancement, reflecting ethical tension despite high interest in modifying non-disease traits. Notably, 50.7% believed that using genetic editing for non-medical purposes crosses ethical boundaries and exceeds nature's limits. Awareness of gene-editing techniques was not significantly associated with acceptance (p = 0.108). In conclusion, public acceptance of gene editing in Taif is high, particularly among healthcare-affiliated individuals. Increasing public awareness remains essential to bridge ethical concerns and support informed engagement.

Open article ↗



2026-09-06 | Kenya Sickle Cell Disease Public Health Literacy & Expert Insights Dataset (De-Identified FGDs, KIIs & Surveys)

This dataset contains de-identified qualitative and survey data collected to understand public health literacy, care experiences, and expert perspectives on sickle cell disease (SCD) in Kenya. The collection includes transcripts from Focus Group Discussions (FGDs) with people living with SCD and caregivers, Key Informant Interviews (KIIs) with Ministry of Health officials, healthcare providers, community representatives, and community health promoters (CHPs), as well as technical expert discussions and structured survey responses. The dataset captures themes related to SCD awareness, diagnosis and treatment pathways, access to care, psychosocial challenges, health information needs, health system barriers, and opportunities for improving community-based support and public health communication. All personal identifiers have been removed to protect participant confidentiality. This resource is intended to support research in public health, health communication, digital health, implementation science, and AI-enabled health systems, and provides contextual insights for the development of culturally appropriate interventions and evidence-based decision support tools for sickle cell disease in low-resource settings.

Open article ↗



2026-08-14 | Augmenting hemopexin-mediated heme scavenging mitigates sepsis-induced acute kidney injury in humanized sickle cell mice.

Sickle cell disease (SCD) is characterized by chronic intravascular hemolysis and depletion of the heme scavenger hemopexin (HPX), generating a high-heme milieu that may increase susceptibility to inflammatory organ injury. Sepsis is a leading cause of acute kidney injury (AKI), yet the contribution of hemolysis-derived free heme to polymicrobial sepsis-associated AKI in SCD remains poorly defined. Using humanized SCD mice, we tested whether augmenting heme clearance via HPX mitigates septic AKI. Low-grade cecal ligation and puncture induced exaggerated systemic inflammation, elevated circulating heme and ferritin, and marked reductions in glomerular filtration rate (GFR) in sickling (hemoglobin SS [HbSS]) mice compared with nonsickling (HbAA) control mice. Septic SS mice also exhibited enhanced renal nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome activation, increased oxidative stress, and tubular injury, consistent with heme-driven inflammatory and cytotoxic signaling. Acute administration of purified human HPX reduced circulating heme and ferritin, attenuated cytokine responses, and preserved GFR, indicating that restoration of heme buffering in SCD interrupts kidney injury pathways during septic stress. To achieve sustained heme control, we restored HPX expression using liver-directed delivery of adeno-associated virus serotype 8 (AAV8). AAV8-HPX restored hepatic HPX, reduced basal and sepsis-induced plasma heme levels, conferred protection against kidney dysfunction and tubular stress, and improved survival without evidence of hepatotoxicity. Collectively, these findings identify free heme as a central mediator linking hemolysis to sepsis-associated AKI in SCD, and establish that HPX augmentation via protein replacement or gene therapy is a mechanistically targeted, potentially translatable therapeutic strategy to mitigate heme-driven tissue injury and improve outcomes in SCD-associated sepsis.

Open article ↗



2026-08-06 | An ancient mitochondrial program tunes translation to haem availability.

Anaemia is a major global health burden that affects one-quarter of the human population and annually accounts for over 50 million years of healthy life lost1. It arises from nutritional iron deficiency, hereditary disorders (including thalassaemia and sickle cell disease) and malaria, and is characterized by haemoglobin imbalances2. Haem-the active component of haemoglobin-is both essential and potentially toxic, which necessitates tight control of levels. However, the molecular circuitry that monitors haem levels remains obscure. The cytosolic eIF2α kinase HRI counteracts anaemia amid iron deficiency or thalassaemia3,4 by acting as a gatekeeper of translation during erythroid differentiation, which has been attributed to its haem-binding ability5. Here we uncover that haem scarcity is sensed inside mitochondria through an OMA1-DELE1 axis. Mechanistically, haem deficiency triggers OMA1-dependent mitochondrial release of DELE1. In the cytosol, DELE1 releases inhibitory haem from HRI, which enables modifications in a crucial disordered segment of the kinase. We demonstrate that this sensor-actuator operates across human tissues, including erythroid progenitors, and is evolutionarily conserved down to bloodless invertebrates, thus predating the emergence of haemoglobin-based oxygen transport. Notably, pharmacological manipulation of this system enhances fetal globin expression-a central therapeutic objective in haemoglobinopathies. Together, these results reveal a primordial sentinel system that safeguards against haem-related toxicity from the single-cell to the organismic scale.

Open article ↗



2026-08-06 | Biomarker implications of gene editing in hematologic diseases: latest updates from ASH 2025.

The 2025 American Society of Hematology (ASH) Annual Meeting highlighted rapid advances in gene editing for hematologic diseases, with increasing emphasis on precision editing and early exploration of in vivo delivery strategies. Beyond technological development, several measurable parameters are emerging as potential biomarkers, including fetal hemoglobin (HbF), F-cell proportion, HbF/F-cell, editing durability, and long-term clonal monitoring. Clinical studies demonstrated that disruption of the BCL11A enhancer or editing of the HBG1/2 promoter can induce sustained HbF reactivation, which is associated with reduced transfusion burden or transfusion independence in transfusion-dependent β-thalassemia and improved clinical outcomes in sickle cell disease. Near-pancellular HbF distribution and HbF/F-cell levels above anti-sickling thresholds further support the pharmacodynamic value of HbF-related biomarkers. Long-term follow-up studies have also incorporated editing durability and clonal monitoring into safety assessment frameworks. Emerging platforms such as RNA Gene Writer and CD90-targeted virus-like particles have demonstrated the feasibility of in vivo hematopoietic stem cell editing, although challenges related to targeting efficiency, delivery specificity, immunogenicity, and long-term safety remain. Overall, ASH 2025 suggests a shift from achieving gene editing to quantifying efficacy, durability, and safety, with standardized biomarker frameworks likely to play an increasingly important role in future clinical translation.

Open article ↗



2026-07-28 | Public knowledge, attitudes, and ethical views on CRISPR-Cas9 gene editing for genetic diseases in Taif, Saudi Arabia.

Public support for gene editing, particularly for therapeutic purposes, remains strong. Recently, the Ministry of Health in Saudi Arabia approved CRISPR-Cas9 for treating Sickle Cell Disease and beta thalassemia. This study aims to assess the Taif population's opinion on gene editing and their knowledge of genetic modification. In this cross-sectional study, a questionnaire was distributed online from March 2, 2024, to June 15, 2024, to 747 residents of Taif City aged 18 and older. Among the respondents, 14.7% reported that they or their family members suffer from a hereditary disease, and 65.7% either work or study in the healthcare field or have a family member involved in healthcare. Additionally, 50.7% had previously heard of genetic modification. Marital status, number of children, and education level did not significantly influence opinions on genetic editing, whereas affiliation with the healthcare field was significantly associated with greater acceptance (p = 0.023), while a family history of hereditary disease showed a trend toward significance (p = 0.055). Public opinion strongly supports using genetic editing to treat life-threatening diseases in adults and embryos (63.2% and 73.6%, respectively). However, opinions are more divided on non-disease traits. Many respondents expressed interest in enhancing intelligence (73.8%) and strength (75.8%), as well as altering height (67.8%) and hair color (60.7%). While support was strong for therapeutic use, opinions were divided on enhancement, reflecting ethical tension despite high interest in modifying non-disease traits. Notably, 50.7% believed that using genetic editing for non-medical purposes crosses ethical boundaries and exceeds nature's limits. Awareness of gene-editing techniques was not significantly associated with acceptance (p = 0.108). In conclusion, public acceptance of gene editing in Taif is high, particularly among healthcare-affiliated individuals. Increasing public awareness remains essential to bridge ethical concerns and support informed engagement.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

111 orphan drug designations for Sickle cell disease and related diseases, including 8 approved therapies.

111 orphan drug designations for Sickle cell disease and related diseases, including 8 approved therapies.

Drug

Therapy type

Regulator

Orphan designation

Approval

Sponsor

tebapivat

small molecules

FDA

2026-02-19

Agios Pharmaceuticals, Inc.

desidustat

small molecules

FDA

2026-02-04

Zydus Healthcare (USA), LLC,

Nangibotide

peptides

EMA

2025-11-21

Inotrem

fetal hemoglobin activator cereblon (CRBN) E3 ligase-modulating drug

small molecules

FDA

2025-06-23

Bristol-Myers Squibb

(lE, 6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6- heptadiene-3,5-dione)

small molecules

FDA

2025-06-09

Vascarta Inc.

autologous CD34+ cell therapy comprised of hematopoietic stem and progenitor cells base edited with one guide RNA and a single messenger RNA encoding an adenine base editor

cell therapies

FDA

2025-05-30

Beam Therapeutics

rilzabrutinib

small molecules

FDA

2025-05-15

Sanofi US Services Inc.

Mitapivat sulfate

small molecules

EMA

2024-12-13

Agios Netherlands B.V.

(8'-hydroxy-6'-oxo-3'-phenyl-6'H-spiro[cyclopentyl-1,5'-indolazine]-7'-carbonyl) glycine

small molecules

FDA

2024-10-24

KIND Pharmaceuticals LLC

ex vivo manufactured allogeneic red blood cells derived from hematopoietic progenitor cells

cell therapies

FDA

2024-10-07

Safi Biotherapeutics, Inc.

pyrindinyl benzaldehyde

small molecules

FDA

2024-09-04

Illexcor Therapeutics, LLC

l-arginine

other

FDA

2024-05-08

Emory University

Beta-nicotinamide mononucleotide

small molecules

FDA

2023-12-14

Nuvamid SA

a recombinant, humanized single variable domain on a heavy chain (VHH) bispecific antibody that binds with high affinity to human properdin and human serum albumin

antibodies

FDA

2023-08-21

Alexion Pharmaceuticals, Inc.

Tarperprumig

antibodies

EMA

2023-07-25

Alexion Europe

Nicotinamide mononucleotide

small molecules

EMA

2023-06-20

LGD

Autologous CD34+ hematopoietic stem and progenitor cells edited by CRISPR/CAS12a at the HBG1 and HBG2 promoters

cell therapies

FDA

2023-04-26

Editas Medicine, Inc.

Epeleuton

small molecules

EMA

2022-10-11

Afimmune Limited

2-[(1,3-Benzoxazol-2-yl)amino]-N-[2-(2-hydroxyethoxy)ethyl]-1-methyl-1H-benzimidazole-5- carboxamide monophosphate

small molecules

FDA

2022-09-01

Astellas Pharma Global Development, Inc.

15(S)-hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoic acid ethyl ester (15(S)-HEPE-EE)

small molecules

FDA

2022-06-03

Afimmune

Inclacumab

antibodies

FDA

2022-05-24

Global Blood Therapeutics, Inc.

a hemoglobin S polymerization inhibitor

small molecules

FDA

2022-05-16

Global Blood Therapeutics, Inc.

(S)-Pociredir

small molecules

EMA

2022-03-16

Pharma Gateway AB

naproxcinod

small molecules

FDA

2022-02-28

Fera Pharmaceuticals, LLC

Pociredir

small molecules

FDA

2022-02-10

Fulcrum Therapeutics, Inc.

gene-corrected (gc) HBB beta-globin gene variant for SCD drug product

combination

FDA

2021-11-23

Kamau Therapeutics, Inc.

2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride

small molecules

EMA

2021-02-19

Vifor France S.A.

Autologous CD34+ hematopoietic stem and progenitor cells transfected with zinc finger nuclease mRNAs SB-mRENH1 and SB-mRENH2

gene editing enzymes

EMA

2021-02-19

Yes Pharmaceutical Development Services GmbH

ferroportin inhibitor

small molecules

FDA

2021-01-25

Vifor Pharma, Inc.

pyrindinyl benzaldehyde

small molecules

FDA

2021-01-07

Illexcor Therapeutics, LLC

Autologous CD34+ cells transduced ex vivo with a lentiviral vector containing a modified gamma-globin gene

gene therapies

EMA

2020-11-13

PPD Bulgaria EOOD

mitapivat

small molecules

FDA

2020-11-12

Agios Pharmaceuticals, Inc.

Rifaximin

small molecules

FDA

2020-10-28

Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)

Decitabine, tetrahydrouridine

small molecules

EMA

2020-10-19

Novo Nordisk A/S

(S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1h)-yl)-3-hydroxy-2-phenylpropan-1-one

small molecules

EMA

2020-10-19

Novo Nordisk A/S

L-citrulline

small molecules

FDA

2020-10-07

Asklepion Pharmaceuticals, LLC

rADAMTS13 / apadamtase alfa (INN)

proteins

FDA

2020-09-28

Takeda Pharmaceuticals U.S.A., Inc.

Hemopexin (Human)

proteins

FDA

2020-09-23

CSL Behring

a recombinant humanized Fc effector function null IgG1 antibody with kappa light chains (IgG1) that selectively binds to E-selectin to inhibit binding to cellular proteins containing carbohydrate structures with a sialyl Lewis X (sLex) deter

antibodies

FDA

2020-09-18

Pfizer Inc.

6-{(1S)-1-[(2-Amino-6-fluoroquinolin-3-yl)oxy]ethyl}-5-(1H-pyrazol-1-yl)pyridin-2(1H)-one

small molecules

FDA

2020-09-18

Pfizer, Inc.

Tovinontrine

small molecules

EMA

2020-08-21

[INACTIVE] TMC Pharma (EU) Limited

Hemopexin, human

proteins

EMA

2020-07-27

CSL Behring GmbH

exagamglogene autotemcel [Casgevy]

combination

FDA

2020-05-11

2023-12-08

Vertex Pharmaceuticals Inc.

Sodium Nitrite

small molecules

FDA

2020-03-25

AdimaBio LLC

etavopivat

small molecules

FDA

2020-02-19

Novo Nordisk Inc.

Autologous CD34+ cells transduced with gamma globin lentiviral vector

gene therapies

FDA

2020-01-14

Cincinnati Children’s Hospital Medical Center

Autologous CD34+ hematopoietic stem cells with a CRISPR-edited erythroid enhancer region of the BCL11A gene [Casgevy]

combination

EMA

2020-01-09

2024-02-12

Vertex Pharmaceuticals (Ireland) Limited

Autologous CD34+ hematopoietic stem and progenitor cells transfected with zinc finger nuclease messenger RNAs SB-mRENH1 and SB-mRENH2

gene editing enzymes

FDA

2019-06-11

Sangamo Therapeutics, Inc.

deferoxamine

small molecules

FDA

2019-03-15

Theris Medical

Benserazide hydrochloride

small molecules

EMA

2019-01-11

Isabelle Ramirez

olinciguat

small molecules

FDA

2018-06-04

Cyclerion Therapeutics, Inc.

Docosahexaenoic acid ethyl ester

small molecules

EMA

2018-03-21

TurnKey PharmaConsulting Ireland Limited

sirolimus

small molecules

FDA

2018-03-13

Rare Partners srl Impresa Sociale

Sirolimus

small molecules

EMA

2018-01-17

Rare Partners srl Impresa Sociale

Decitabine and tetrahydrouridine

small molecules

EMA

2017-06-20

Ulrich Muehlner

6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one

small molecules

FDA

2017-01-31

Imara Inc.

2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde [Oxbryta]

small molecules

EMA

2016-11-18

2022-02-15

Pfizer Europe MA EEIG

Hepcidin

peptides

EMA

2016-11-18

La Jolla Pharmaceutical II B.V.

decitabine and tetrahydrouridine

small molecules

FDA

2016-09-19

Novo Nordisk Inc.

dodecafluoropentane emulsion

other

FDA

2016-02-11

NuvOx Pharma

Voxelotor [Oxbryta]

small molecules

FDA

2015-12-29

2019-11-25

Global Blood Therapeutics, Inc.

prasugrel hydrochloride

small molecules

FDA

2015-05-26

Eli Lilly

docosahexaenoic acid

small molecules

FDA

2015-04-27

Micelle BioPharma, Inc.

sevuparin

small molecules

FDA

2015-03-17

Modus Therapeutics

hydroxyurea

small molecules

FDA

2015-03-16

Ebelle D'Ebelle Pharmaceuticals LLC

Sevuparin sodium

other

EMA

2015-02-12

Modus Therapeutics AB

5-(hydroxymethyl)-2-furaldehyde [BAX 555]

small molecules

EMA

2015-02-12

BAXALTA INNOVATIONS GmbH

pegylated carboxyhemoglobin bovine

proteins

FDA

2015-01-15

Prolong Pharmaceuticals, LLC

6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydro-pyran-4-yl)-1,5-dihydro-pryazolo[3,4-d]pyrimidin-4-one

small molecules

FDA

2014-09-04

Cardurion Pharmaceuticals, Inc.

Betibeglogene autotemcel [Zynteglo]

gene therapies

EMA

2014-04-29

bluebird bio (Netherlands) B.V.

lovotibeglogene autotemcel [Lyfgenia]

gene therapies

FDA

2014-02-26

2023-12-08

Genetix Biotherapeutics Inc.

human haptoglobin

proteins

FDA

2013-11-19

BioProducts Laboratory Limited

Rivipansel

small molecules

EMA

2013-08-05

FGK Representative Service GmbH

hydroxycarbamide (hydroxyurea) [Siklos]

small molecules

FDA

2013-07-24

2017-12-21

Theravia Pharma

recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)

antibodies

FDA

2013-04-12

NKT Therapeutics, Inc.

Poloxamer 188 [ANX-188 (purified poloxamer 188) Injection]

small molecules

EMA

2013-03-12

Theradex (Europe) Limited

extract of sorghum bicolor extract

other

FDA

2012-11-19

Invenux, LLC

carbon monoxide

small molecules

FDA

2012-09-28

Hillhurst Biopharmaceuticals, Inc.

Crizanlizumab [Adakveo]

antibodies

EMA

2012-08-09

Novartis Europharm Limited

Levoglutamide

small molecules

EMA

2012-07-04

Emmaus Medical Europe Limited

Human erythrocytes encapsulating inositol hexaphosphate

small molecules

EMA

2012-07-04

ERYtech Pharma S.A.

Human haptoglobin

proteins

EMA

2011-12-09

Kedrion S.p.A.

pentosan polysulfate sodium

small molecules

FDA

2011-09-16

Vanguard Therapeutics, Inc.

Deferiprone

small molecules

EMA

2011-02-23

Chiesi Farmaceutici S.p.A.

pegylated carboxyhemoglobin

proteins

FDA

2010-10-21

Sangart, Inc.

Pegylated carboxyhaemoglobin

proteins

EMA

2009-11-26

Voisin Consulting Life Sciences

2,2-dimethylbutyric acid, sodium salt

small molecules

EMA

2009-03-18

Isabelle Ramirez

(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-

small molecules

FDA

2009-02-17

GlycoMimetics, Inc.

pentosan polysulfate sodium

small molecules

FDA

2008-11-21

TRF Pharma, Inc.

nitric oxide

small molecules

FDA

2008-09-05

Mallinckrodt Pharmaceuticals Ireland Ltd.

sodium 2, 2 dimethylbutyrate

small molecules

FDA

2008-07-25

HemaQuest Pharmaceuticals, Inc.

crizanlizumab [ADAKVEO]

antibodies

FDA

2008-07-22

2019-11-15

Novartis Pharmaceuticals Corporation

varespladib sodium

small molecules

FDA

2007-11-19

Anthera Pharmaceuticals, Inc.

sodium nitrite

small molecules

FDA

2007-04-02

Hope Pharmaceuticals

5-hydroxymethyl-2-furfuraldehyde

small molecules

FDA

2006-05-26

Baxalta US, Inc.

Extract of Sorghum bicolour leaf, Pterocarpus osun stem, Piper guineense seed and Caryophylli flower

other

EMA

2005-08-26

Xechem UK Ltd

oral unfractionated heparin

small molecules

FDA

2004-01-29

TRF Technologies, Inc.

niprisan

other

FDA

2003-08-15

Xechem International, Inc.

Hydroxycarbamide [Siklos]

small molecules

EMA

2003-07-09

[INACTIVE] Addmedica

N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea

small molecules

FDA

2002-05-13

NeuroSearch A/S

L-glutamine [Endari]

small molecules

FDA

2001-08-01

2017-07-07

Emmaus Medical, Inc.

Bis(4-fluorophenyl)phenylacetamide

small molecules

FDA

2000-03-02

ICAgen Inc.

Fructose-1,6-diphosphate

small molecules

FDA

1998-05-29

Questcor Pharmaceuticals, Inc.

Clotrimazole

small molecules

FDA

1995-04-24

Brugnara, Carlo M.D.

Arginine butyrate

small molecules

FDA

1994-05-25

Vertex Pharmaceuticals Inc.

sodium phenylbutyrate

small molecules

FDA

1992-07-02

Medicis Pharmaceutical Corp.

Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid

small molecules

FDA

1991-10-24

Omex International, Inc.

Lysine acetylsalicylate injectable

small molecules

FDA

1989-08-01

G.D. Searle & Company

poloxamer 188 (purified)

small molecules

FDA

1989-06-27

Mast Therapeutics Inc.

Cetiedil citrate injection

small molecules

FDA

1988-12-22

Baker Cummins Pharmaceuticals, Inc.

substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits

small molecules

FDA

1987-10-23

Burroughs Wellcome Company

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.